Skip to main content

Advertisement

Fig. 2 | Journal of Translational Medicine

Fig. 2

From: A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

Fig. 2

Serum biomarkers in peripheral spondyloarthritis. Effect of nilotinib and placebo on serum biomarkers of patients with peripheral spondyloarthritis. The panel represents the C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), calprotectin and matrix metalloproteinase-3 (MMP-3) levels before (week 0) and after treatment (week 12) with nilotinib (ad) or placebo (eh). The lines connect the data points for each patient. *P value <0.05

Back to article page